



Challenge TB - UN Special Envoy TB

Year 2

Quarterly Monitoring Report January-March 2016

Submission date: April 29, 2016

Table of Contents

1. QUARTERLY OVERVIEW	3
2. CHALLENGE TB-SUPPORTED INTERNATIONAL VISITS (TECHNICAL AND MANAGEMENT-RELATED TRIPS)	5
3. FINANCIAL OVERVIEW	7

Cover photo:

This report was made possible through the support for Challenge TB provided by the United States Agency for International Development (USAID), under the terms of cooperative agreement number AID-OAA-A-14-00029.

Disclaimer

The authors' views expressed in this publication do not necessarily reflect the views of the United States Agency for International Development or the United States Government.

1. Quarterly Overview

Country	Core UN Special Envoy TB
Lead Partner	UCSF, subcontracted through KNCV Tuberculosis Foundation
Other partners	
Workplan timeframe	October 2015 – September 2016
Reporting period	January-March 2016

Summary progress report:

During this period we have refined the strategy for the UNSE and are focused on 5 principal objectives; i) supporting efforts to secure international funding (Global Fund, other donor countries, following G7/G20 agenda etc.); ii) high burden country engagement; iii) use AMR agenda to secure TB research dollars; iv) writing a Lancet Commission on TB, and v) participation in key fora (HLM HIV, TB 2016, The Union, etc.)

Updates:

- Global Fund replenishment support – trip planned for Australia / PNG (June 27) to encourage AU government to commit to the GF replenishment and urge them to take a leadership role in TB in Asia.
- G7 – working with stakeholder to try to raise the issue of Tuberculosis within the construct of Japan’s priorities notably Universal Health Care (UHC). Confirmed placement of OpEd in Japan in the run up to G7 meeting on UHC / TB. Publication expected in early May.
- Anti-Microbial Resistance (AMR) as a source of new TB R&D funding – ongoing engagement with AMR Review team (UK). Provided editorial comments for their 3 latest publications with the goal of keeping TB on the AMR agenda and ensuring that their proposals support the needs of TB. Eric serves as an advisor to the AMR Review team and we are currently looking for ways for Eric to participate in the report launch and build up to United Nations General Assembly (UNGA) 2016
- Nigeria – confirmed planning for advocacy trip to Nigeria scheduled for May 16-19. Coordinating with various stakeholders to understand the TB situation in Nigeria and to optimize the impact of the meeting.
- China – we initiated discussions with a variety of stakeholders to evaluate the potential for a high level visit to China in 2016.
- UN HLM (High Level Meeting) on HIV/AIDS –participated in background meetings and drafted key messages on TB and an advocacy plan. Met with various advocacy groups to try to ensure participation in the civil society consultation (April 6th). Goal is that the language of the declaration provides clear support to essential strategies necessary to reduce mortality in TB/HIV co-infected patients
- Pediatric TB – Engaged with TB referent in UNICEF to coordinate meeting with the head of UNICEF (Dr. Anthony Lake) to explore how the organization can be more broadly engage in pediatric TB diagnosis and treatment. Supported UNICEF/ TB Alliance in the launch of “Louder than TB” communications campaign.
- Lancet Commission – prepared concept note for review by the Lancet Commission. Concrete discussions with Richard Horton (Editor) started in April.

Events

- World Bank Conference in DC – Jane Coyne represented Dr. Goosby at the WB Conference on Allocative Efficiency (Feb 3-4)
- CROI – Jane Coyne attended CROI and associated TB side meetings to stay current on research and connect with stakeholders (notably PIH). Side meetings included TB/HIV meeting sponsored by WHO and the TB Diagnostics Symposium at the Harvard School of Public Health (Feb 22-26)
- WHO Public Private Mix on TB – working group meeting on TB. Meeting provided excellent overview of challenges and pilot successes in private sector engagement. Visit allowed baseline preparation for potential future visit of the UNSE. Additional visits to Foundation for Medical Research and Hinduja Hospital. (Feb 29 – Mar 4).

Press releases / Communications:

- Jan 7th – supporting release of MDR Action plan
- Feb 9th – Condemning Administration for cutting 2017 TB budget
- March 24th – World TB Day - Huffington Post – “Giving voice to the voiceless”
- March 24th – World TB Day - Press Statement on TB
 - o <http://www.tbenvoy.org/statement-from-un-special-envoy-on-tuberculosis-eric-p-goosby-on-world-tb-day-march-24-2016/>
- March 24th – Interview with Dr. Goosby
 - o <http://globalhealthsciences.ucsf.edu/news-events/un-special-envoy-eric-goosby-answers-five-questions-about-tb>
- Website – the official website for the UNSE on TB has launched after months of work.
Link for website = <http://www.tbenvoy.org/news/>

Technical/administrative challenges and actions to overcome them:

UCSF financial systems are complex and slow moving. The contract set up process was challenging but this does not represent a risk to the project. Documentation and system set up are complete. We are going to review all the technical aspects of grant management now that all costs have been allocated to the system. Review to be completed by May 1 and with that we will be able to provide feedback regarding overall utilization and any potential grant revisions.

2. Challenge TB-supported international visits (technical and management-related trips)

#	Partner	Name of consultant	Planned quarter					Specific mission objectives	Status (cancelled, pending, completed)	Dates completed	Duration of visit (# of days)	Additional Remarks (Optional)
			Q 4	Q 1	Q 2	Q 3	Q 4					
1	UCSF	Dr. Eric Goosby	X					Launch of WHO TB 2015 report	Completed	Oct 29, 2015	3	
2	UCSF	Dr. Eric Goosby	X					Participation in WHO Civil Society Consultation – Addis Ababa	Completed	November 11, 2015	4	Trip principally paid for by another donor
3	UCSF	Dr. Eric Goosby / Jane Coyne	X					The Union Meeting, Stop TB Partnership board meeting, Global TB Caucus	Completed	December 6, 2015	8	
4	UCSF	Dr. Eric Goosby / Jane Coyne	X					Congressional testimony on Drug Resistant TB	Completed	December 10, 2015	2	
5	UCSF	Jane Coyne		X				World Bank Conference on Allocative Efficiency	Completed	February 4, 2016	2	
6	UCSF	Jane Coyne		X				CROI – Conference in Boston + WHO conference on TB/HIV co-infection	Complete	February 25, 2016	4	
7	UCSF	Jane Coyne		X				WHO PPM Working Group Meeting – Mumbai India + ground work for potential TB visit	Complete	March 4, 2016	6	
8	UCSF	Eric Goosby, Amy Lockwood, Jane Coyne			X			IAS Durban + Tb 2016	Pending	July 22, 2016		Note – this is pre-payment to reduce cost for IAS conference in July
9					X			Head of State Visit	Pending			
10		Dr Eric Goosby, Jane Coyne			X			UN HLM on HIV – Unga June 2016	Pending			

10					X			World Health Assembly	Pending			
11						X		Head of State Visit	Pending			
12						X		African Union Meeting	Pending			
13							X	The Union Meeting	Pending			
Total number of visits conducted (cumulative for fiscal year)									7			
Total number of visits planned in approved work plan									13			
Percent of planned international consultant visits conducted									54%			

3. Financial overview

Challenge TB Quarterly financial report

Country	UN Special Envoy
Lead partner	KNCV

Period:	Jan 2016 - March 2016
---------	-----------------------

	Total
Total obligation	932,790
Total budgeted	-
Funds to be programmed	932,790
Total expenditures	264,875
Pipeline	667,915
Remarks to this overview	

	Total expenditures excl. ACF
Exp Jan-March 2016	228,928
Exp Oct-Dec 15	968
Exp July-Sept 15	
Exp April-June 15	
Average burn rate	114,948

Year 2

Partner	Approved budget	Previously reported expenditures	Reported expenditures this quarter	Accruals this quarter	Total expenditures	Remaining funds	% level of spending
KNCV	862,830	968	228,928	-	229,895	632,935	27%
ACF	69,959	17,490	17,490	-	34,980	34,979	50%
TOTAL	932,790	18,458	246,417	-	264,875	667,915	28%

Budget category	Approved budget	Previously reported	Reported this quarter	Accruals this quarter	Total expenditures	Remaining funds	% level of spending
Salary and wages	302,355	574	127,184		127,758	174,597	42%
Fringe benefits	177,459	-	61,490		61,490	115,969	35%
Travel and transportation	150,126	-	36,840		36,840	113,286	25%
Equipment	4,500	-	-		-	4,500	0%
Supplies	3,334	-	-		-	3,334	0%
Other Direct Costs	5,000	-	1,249		1,249	3,751	25%
Indirect costs	220,057	394	2,165		2,558	217,499	1%
ACF	69,959	17,490	17,490		34,980	34,979	50%
TOTAL	932,790	18,458	246,417	-	264,875	667,915	28%

Budget category	Approved budget	Previously reported	Reported this quarter	Accruals this quarter	Total expenditures	Remaining funds	% level of spending
7. Political commitment and leadership	201,169	-	36,840		36,840	164,329	18%
Staffing and operations	661,662	968	192,088		193,055	468,606	29%
ACF	69,959	17,490	17,490		34,980	34,979	50%
TOTAL	932,790	18,458	246,417	-	264,875	667,915	28%

Budget category	Approved budget	Previously reported	Reported this quarter	Accruals this quarter	Total expenditures	Remaining funds	% level of spending
HQ costs	932,790	18,458	246,417	-	264,875	667,915	28%
TOTAL	932,790	18,458	246,417	-	264,875	667,915	28%